Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
FOMX was delisted on the 6th of March, 2020.
66 hedge funds and large institutions have $116M invested in Foamix Pharmaceuticals Ltd. Ordinary Shares in 2018 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 21 increasing their positions, 25 reducing their positions, and 18 closing their positions.
12% less funds holding
Funds holding: 75 → 66 (-9)
16% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 25
18% less call options, than puts
Call options by funds: $145K | Put options by funds: $177K
39% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 18
41% less capital invested
Capital invested by funds: $197M → $116M (-$80.7M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$7.51M |
| 2 |
PA
Perceptive Advisors
New York
|
+$6.76M |
| 3 |
SM
Senvest Management
New York
|
+$3.29M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$3.23M |
| 5 |
Man Group
London,
United Kingdom
|
+$1.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DA
DSC Advisors
Chicago,
Illinois
|
-$9.86M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.62M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$6.3M |
| 4 |
NC
Nexthera Capital
New York
|
-$4.28M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.29M |
FOMX Hedge Fund Activity: Q4 2018 in Review
66 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) for Q4 2018, worth a combined $116M — down 41% from $197M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of FOMX and 11 opened new positions — a net loss of 7 holders — while 25 trimmed existing stakes and 21 added.
The largest buyer was UBS Group, adding an estimated $7.51M. The largest seller was DSC Advisors, exiting entirely with an estimated $9.86M sold.
- 66 institutional investors held Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) as of Q4 2018, down from 75 in Q3 2018.
- Funds reported $116M of Foamix Pharmaceuticals Ltd. Ordinary Shares stock for Q4 2018, down 41% quarter-over-quarter.
- 11 funds opened new Foamix Pharmaceuticals Ltd. Ordinary Shares positions in Q4 2018 and 18 closed out, a net change of -7 holders.
- The largest Foamix Pharmaceuticals Ltd. Ordinary Shares buyer in Q4 2018 was UBS Group, an estimated $7.51M added.
- The largest Foamix Pharmaceuticals Ltd. Ordinary Shares seller in Q4 2018 was DSC Advisors, an estimated $9.86M sold.
Based on aggregated 13F filings for Q4 2018.